Aimmune Therapeutics Inc (NASDAQ:AIMT) – Investment analysts at Piper Jaffray Companies reduced their FY2022 EPS estimates for shares of Aimmune Therapeutics in a research report issued to clients and investors on Thursday, November 8th. Piper Jaffray Companies analyst C. Raymond now forecasts that the biotechnology company will earn $3.05 per share for the year, down from their prior forecast of $3.06.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.03.

Several other equities research analysts have also issued reports on the company. Roth Capital set a $80.00 price target on Aimmune Therapeutics and gave the company a “buy” rating in a report on Sunday. Credit Suisse Group set a $40.00 price target on Aimmune Therapeutics and gave the company a “buy” rating in a report on Friday. ValuEngine upgraded Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 1st. Wedbush assumed coverage on Aimmune Therapeutics in a report on Wednesday, October 17th. They set a “buy” rating and a $72.00 price target for the company. Finally, BidaskClub upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 16th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $50.70.

Shares of Aimmune Therapeutics stock opened at $30.29 on Monday. Aimmune Therapeutics has a 52-week low of $24.56 and a 52-week high of $42.00.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tiverton Asset Management LLC acquired a new stake in Aimmune Therapeutics in the 2nd quarter worth approximately $145,000. Ardsley Advisory Partners acquired a new stake in Aimmune Therapeutics in the 2nd quarter worth approximately $202,000. Xact Kapitalforvaltning AB acquired a new stake in Aimmune Therapeutics in the 1st quarter worth approximately $207,000. Atria Investments LLC acquired a new stake in Aimmune Therapeutics in the 3rd quarter worth approximately $213,000. Finally, Fred Alger Management Inc. acquired a new stake in Aimmune Therapeutics in the 2nd quarter worth approximately $269,000. Hedge funds and other institutional investors own 78.16% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Recommended Story: Asset Allocation

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.